About Community Pharmacy South Central
Continuously improving the quality of care we give patients and
improving the outcomes of their treatment is the core purpose of
the new NHS commissioning system.
The latest news
Information on training events and resources available for you and your team
Written by admin on Wednesday 18th October 2017
Certain pages on this news feed are only available to NPA members and hence requires members to log-in accordingly
They take place across England from August to October, and the NPA encourages you to attend. Find out more on PSNC’s website…
Following the recent Department of Health and Social Care (DHSC) Supply Disruption Alert for Emerade, the NPA Pharmacy Services Team has received a number of queries from NPA members regarding suitable alternatives and actions to take to support affected patients.
The supply disruption alert included a management plan to manage the shortages of the affected Emerade adrenaline auto injector (AAI) devices:
Emerade 300 micrograms – Bausch & Lomb UK Ltd — limited supplies available with further supplies expected by the end of September 2019
Emerade 500 micrograms – Bausch & Lomb UK Ltd — out of stock with supplies expected on 28 August 2019
Alternative AAIs and stock availability as of 6/8/19:
Epipen® 0.3mg manufactured by Mylan
Stock availability — In stock through a prescription validation service, as below
Send anonymized prescriptions to Alliance Healthcare, either by fax to 0330 332 8126 or email email@example.com
Include your Alliance Healthcare account number
A maximum of two devices per prescription can be ordered
Jext 300 micrograms manufactured by Alk Abello Ltd
Stock availability — In stock with Alliance Healthcare, delivered weekly ony
Implications for patients
Neither of the alternatives, EpiPen or Jext, is available in a 500 microgram strength AAI. Therefore, according to the supply disruption alert: “The advice from national experts is, in the absence of Emerade 500 microgram, affected patients should be prescribed 300 microgram AAIs and advised to keep at least two pens with them at all times”.…
The Manage Your Service (MYS) application will be the only platform for making declarations and claiming for the Pharmacy Quality Scheme (PQS). Please note the Snap Survey will not be used.
The MYS application will be used for claiming payment for the Flu Vaccination Service 2019/2020 and notifying readiness for the implementation of the Community Pharmacist Service Consultation (CPCS). Registration with the MYS application is also required for pharmacies claiming aspiration payments during October 2019. You are reminded to register for MYS through the NHS Business Services Authority (NHSBSA).
An access authorisation form, available on the NHSBSA website, must be completed by the business owner, director, or an individual previously registered with the Information Services Portal. A pharmacy or an individual can be registered through this form.
Registration typically takes 2-5 working days once the NHSBSA has received the application. After authorisation, pharmacy staff will be able to access the MYS portal using a smartcard or individual NHSmail credentials.
How to register
Access the NHSBSA website and download the MYS Access Authorisation Form.
Complete pharmacy details.
Provide details of all individuals who will have access to the MYS application within the pharmacy. Specify what level of access is required (pharmacy level access or management level access); unless stated, users will only be granted pharmacy level access by default.…
Class 2 medicines recall – Action within 48 hours – Aripiprazole oral solution 1mg/ml
Ref: (EL (19)A/20)
Date 30 July 2019
Aripiprazole oral solution 1mg/ml
(Manufactured by Accord-UK )
A Class 2 medicines recall has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for certain batches of Aripiprazole oral solution 1mg/ml manufactured by Accord-UK (in Actavis packaging) as stated below.
Accord-UK has recalled the batches above due to the possibility of the presence of small particles of Aripiprazole active material which may affect the efficacy of the product.
Further information can be found on the MHRA section on the GOV.UK website.
Produced by the NPA Pharmacy team July 2019.
The Competition and Markets Authority (CMA) has found provisionally that sellers of the antibiotic Nitrofurantoin broke competition law by arranging to carve up the market between them.
Alliance Healthcare and two manufacturers – Morningside and AMCo (now Advanz) – are alleged by the CMA to have entered into anticompetitive agreements to keep prices of nitrofurantoin artificially high.
A NPA spokesperson said:
“As well as costing taxpayers, independent community pharmacists can lose out if restricted choice leads to higher medicines prices.”
“At a time when community pharmacies are being asked to make efficiencies to help manage primary care budgets, it is galling to read that some of the cost pressures may be caused by suppliers and wholesalers behaving anti-competitively.”
The CMA’s findings are provisional and the allegations have been denied.
Drug (pack size)
Alverine capsules 60mg (100)
Betahistine tablets 8mg (84)
Betahistine tablets 16mg (84)
Bumetanide tablets 1mg (28)
Buspirone tablets 10mg (30) (NEW)
Cefalexin oral suspension 250mg/5ml (100ml)
Celecoxib capsules 200mg (30)
Co-amilofruse tablets 5mg/40mg (28) (NEW)
Cyclizine solution for injection ampoules 50mg/1ml (5) (NEW)
Diamorphine powder for solution for injection ampoules 10mg (5)
Diamorphine powder for solution for injection ampoules 30mg (5)
Escitalopram tablets 10mg (28) (NEW)
Escitalopram tablets 20mg (28)
Escitalopram tablets 5mg (28) (NEW)
Finasteride tablets 5mg (28)
Hydroxychloroquine tablets 200mg (60)
Ibandronic Acid tablets 150mg (28)
Indapamide tablets 2.5mg (28) (NEW)
Irbesartan tablets 150mg (28) (NEW)
Irbesartan tablets 300mg (28) (NEW)
Losartan tablets 12.5mg (28)
Metoprolol tablets 50mg (28)
Metoprolol tablets 100mg (28)
Mometasone nasal spray 50micrograms/dose (140) (NEW)
Montelukast tablets 10mg (28) (NEW)
Naproxen gastro-resistant tablets 250mg (56)
Nebivolol tablets 5mg (28)
Pantoprazole gastro-resistant tablets 20mg (28)
Pantoprazole tablets gastro-resistant 40mg (28)
Prednisolone tablets 5mg (28)
Prednisolone sodium phosphate ear/eye drops 0.5% (10ml)
Quetiapine tablets 200mg (60)
Quetiapine tablets 25mg (60) (NEW)
Quinine sulphate tablets 200mg (28)
Quinine sulphate tablets 300mg (28)
Riluzole tablets 50mg (56) (NEW)
Risedronate sodium tablets 35mg (4)
Tamoxifen tablets 20mg (30)
Tolbutamide tablets 500mg (28)
Topiramate tablets 100mg (60)(NEW)
Topiramate tablets 50mg (60)
Valsartan 160mg / Hydrochlorothiazide 12.5mg tablets (28)
Valsartan capsules 160mg (28)
Valsartan capsules 80mg (28) (NEW)
Unfortunately this will be my last superintendent update that I am sending to you. After nearly 10 years at the NPA the time has come for me to move on to a new adventure. I am very proud of the achievements of the brilliant pharmacy services team over these past years, I hope you will agree with me that we consistently tried to go over and beyond in what we do.
I want to take this opportunity to thank you as my colleagues across the U.K. for believing in me and providing me with the opportunity to support you and represent our profession out there. You have made me feel that my work is appreciated and in my view nothing is more rewarding than that in someone’s career. I have been very lucky to have enjoyed great relationships with my colleagues in the sector and established great friendships with many of you, which I value a lot. I look forward to continuing working with you moving forward. My contact details are below. I hope you will keep in touch.
Tel: 0750 8932 868
MSO quarter 2 report
I am pleased to publish my Medication Safety Officer’s (MSO) report for Quarter 2 (Q2) of 2019, please click here to download https://www.npa.co.uk/wp-content/uploads/2019/07/MSO-report-Q2-of-2019.pdf.…
AYP Week provides a platform for pharmacy public awareness activities across the UK. It also serves as a prompt for conversations with key stakeholders at a local level about community pharmacy services. During previous AYP Weeks:
NHS bodies have used social media and local newspapers to signpost people to community pharmacy as the first port of call for common ailments
Pharmacies have invited local dignitaries and politicians to visit for a health check and to learn more about the valuable services on offer
NPA members have displayed window posters and other campaign materials, available free of charge from the NPA
Pharmacies and local pharmacy representatives have organised exhibitions in town halls, shopping centres and sports venues
More details will be published soon. Meanwhile, any NPA member or pharmacy stakeholders wishing to get involved should contact NPA Head of Communications, Stephen Fishwick, for more information firstname.lastname@example.org…
With the launch of the green paper, DHSC is seeking views on proposals to tackle the causes of preventable ill health in England.
It outlines actions on
the environment in which people live
the choices people make
the services people receive
The government says it intends to:
Embed genomics in routine healthcare
Review the NHS Health Check and set out a bold future vision of NHS screening
Launch phase one of a ‘Predictive Prevention’ (data driven) work programme from Public Health England
The NPA briefed the policy team preparing this document, which also talks about expanding the role of community pharmacists to “support more people in the community to manage and improve their health and wellbeing”. It continues, “We will commission more services from community pharmacies and support them to become further integrated into local NHS provider networks.”
The changes to the Community Pharmacy Contractual Framework in England announced in July include a pipeline of prevention-focused pharmacy based services, including helping to identify and refer patients with unidentified health conditions such as heart disease. Over the course of the settlement period all pharmacies in England will become Healthy Living Pharmacies which will require them to have trained health champions on site.…
Class 2 medicines recall – Action within 48 hours – Bisacodyl Gastro-Resistant tablets 5mg
Ref: EL (19)A/18
Date 24 July 2019
Bisacodyl Gastro-Resistant tablets 5mg
(Manufactured by Chanelle Medical)
A Class 2 medicines recall has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for a specific batch of Bisacodyl Gastro-Resistant tablets 5mg manufactured by Chanelle Medical.
1 x 1000 tablets
19 May 2018
The manufacturer has recalled the batch because a small number of affected packs contain tablets which are stuck together. In addition, mould has been found on some tablets, this has been identified to be a Penicillium species. It is considered unlikely that patients would have received affected tablets because sticking is evident when the pack is opened.
Pharmacy teams should:
Immediately stop supplying tablets from the affected batches, quarantine all remaining stock and return it to the supplier using the approved process
Be aware that although only the above batch has been recalled, a number of batches were manufactured at the same time
Notify Chanelle Medical and return (to the supplier) any other batches affected by tablets which are stuck together or where mould can be seen
Ensure that all medicines are stored within manufacturers’ storage requirements as stated in the Summary of Product Characteristics (SPC)
The SPC for Bisacodyl Gastro-Resistant tablets 5mg states “Do not store above 25°C.…